Suppliers / Chongqing Southwest No.2 Pharmaceutical Factory

Chongqing Southwest No.2 Pharmaceutical Factory

China Updated 9 July 2026

Chongqing Southwest No.2 Pharmaceutical Factory is an API manufacturer based in China. It holds one active US drug master file and one valid CEP across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 31 May 2024 as VAI.

1
active US DMFs
1
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 31 May 2024 VAI US FDA
  • 28 April 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3008857790
Chongqing, China Not on file

What they file, and where

Molecule Regulators Docs
Benzocaine US FDA 1
Procaine EDQM 1

Also appears on these molecule pages

Benzocaine API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Chongqing Southwest No.2 Pharmaceutical Factory

Does Chongqing Southwest No.2 Pharmaceutical Factory hold a US DMF or a CEP?
Chongqing Southwest No.2 Pharmaceutical Factory holds 1 active US drug master file and 1 valid CEP. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Chongqing Southwest No.2 Pharmaceutical Factory FDA-registered?
One site operated by Chongqing Southwest No.2 Pharmaceutical Factory carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Chongqing Southwest No.2 Pharmaceutical Factory's last inspection go?
The most recent inspection on record closed on 31 May 2024 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 2 inspections are on file.
Where does Chongqing Southwest No.2 Pharmaceutical Factory manufacture?
2 registered sites are on record, in China (China and Chongqing). Every site is listed on this page with the register it came from.
What does Chongqing Southwest No.2 Pharmaceutical Factory make?
2 molecules are on record against Chongqing Southwest No.2 Pharmaceutical Factory, including Benzocaine and Procaine. Each links through to that molecule's full manufacturer list.
Which regulators recognise Chongqing Southwest No.2 Pharmaceutical Factory's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Chongqing Southwest No.2 Pharmaceutical Factory comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 31 May 2024.

Comparable suppliers

Apex Healthcare shares 1 molecule Zhejiang Bamboo Pharmaceuticals Co., Ltd shares 1 molecule Jinzhou Jiutai Pharmaceutical shares 1 molecule Changzhou Sunlight Pharmaceutical shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates